Radiopharm Theranostics Appoints Leading Prostate Cancer Expert Dr. Oliver Sartor to Scientific Advisory Board
Key Insights
Radiopharm Theranostics has appointed Dr. Oliver Sartor, an internationally recognized medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board.
Dr. Sartor currently serves as Director of Radiopharmaceutical Clinical Trials at Mayo Clinic and has led multiple pivotal Phase 3 trials resulting in FDA approvals for radiopharmaceutical therapies.
The appointment strengthens Radiopharm's clinical expertise as the company advances its radiopharmaceutical pipeline, which includes one Phase 2 and three Phase 1 trials across various solid tumor cancers.
Radiopharm Theranostics, a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals, announced the appointment of Dr. Oliver Sartor, MD, to its Scientific Advisory Board. The strategic addition brings significant expertise in radiopharmaceutical therapies and prostate cancer research to the company's leadership team.
Distinguished Clinical Background
Dr. Sartor is an internationally recognized medical oncologist and scientist specializing in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the Mayo Clinic in Rochester, Minnesota. Previously, he held the position of Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine.
His career includes senior roles at LSU Health Sciences Center, Dana-Farber/Harvard Medical School, and as Medical Oncology Co-Chair of the GU Committee of NRG Oncology. Dr. Sartor received his MD with honors from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and completed a medical oncology fellowship at the National Cancer Institute.
Proven Track Record in Drug Development
Since 1990, Dr. Sartor has focused on prostate cancer clinical research, authoring more than 500 peer-reviewed publications. His clinical research leadership has been instrumental in advancing radiopharmaceutical therapies, having led multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium-153 EDTMP (search), cabazitaxel, radium-223, and PSMA (search)-targeted radioligand therapy.
"Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies," said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. "We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline."
Company Pipeline and Platform
Radiopharm Theranostics is developing a platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company is listed on ASX (RAD) and NASDAQ (RADX), with a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer.
The company's clinical program currently includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. This diverse portfolio positions the company to address multiple oncology indications through its radiopharmaceutical approach.